Prilenia is dedicated to developing new treatments for patients and families facing neurodegenerative diseases and neurodevelopmental disorders, such as Huntingtonβs disease and amyotrophic lateral sclerosis (ALS). They focus on harnessing the brain's neuroprotective capabilities, particularly through the activation of the sigma-1 receptor (S1R), to restore impaired pathways in the brain. Prilenia is advancing scientific research and exploring potential treatments to provide hope and improve the lives of patients and their families.
11 - 50 employees
𧬠Biotechnology
π Pharmaceuticals
βοΈ Healthcare Insurance
π° $43M Series B on 2021-11
October 20
Senior Statistical Programmer at Prilenia Therapeutics for neurodegenerative disease research.
πΊπΈ United States β Remote
π° $43M Series B on 2021-11
β° Full Time
π Senior
π₯ Software Engineer
October 20
Lead Market Access strategy for Prilenia's neurotherapeutics across Europe.
π³π± Netherlands β Remote
π° $43M Series B on 2021-11
β° Full Time
π΄ Lead
π Vice President
October 20
Oversee DS GMP production activities at Prilenia Therapeutics.
October 20
Lead clinical development strategy for neurodegenerative therapies at Prilenia.
πΊπΈ United States β Remote
π° $43M Series B on 2021-11
β° Full Time
π Senior
π Vice President
October 20
Lead finance for Prilenia Therapeutics, focusing on neurodegenerative treatments.
πΊπΈ United States β Remote
π° $43M Series B on 2021-11
β° Full Time
π΄ Lead
πΈ Financial Planning and Analysis